Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients | Zendy

Natalie Bath | Zendy; Arjang Djamali | Zendy; Sandesh Parajuli | Zendy; Didier A. Mandelbrot | Zendy; Glen Leverson | Zendy; Luis Hidalgo | Zendy; Thomas M. Ellis | Zendy; Jillian L. Descourouez | Zendy; Margaret R. Jorgenson | Zendy; Dave Hager | Zendy; Dixon B. Kaufman | Zendy; Robert R. Redfield | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients

Author(s) -

Natalie Bath,

Arjang Djamali,

Sandesh Parajuli,

Didier A. Mandelbrot,

Glen Leverson,

Luis Hidalgo,

Thomas M. Ellis,

Jillian L. Descourouez,

Margaret R. Jorgenson,

Dave Hager,

Dixon B. Kaufman,

Robert R. Redfield

Publication year - 2020

Publication title -

kidney360

Language(s) - English

Resource type - Journals

ISSN - 2641-7650

DOI - 10.34067/kid.0000122020

Subject(s) - alemtuzumab , basiliximab , medicine , incidence (geometry) , induction therapy , donor specific antibodies , gastroenterology , kidney transplantation , transplantation , anti thymocyte globulin , oncology , immunology , chemotherapy , physics , optics

Optimal induction for patients without pretransplant donor-specific antibodies (DSAs) is poorly defined. The goal of this study was to compare the incidence of de novo DSA (dnDSA) and graft outcomes between induction therapies in patients with a negative virtual crossmatch (VXM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research